Serum protein profile of Crohn's disease treated with infliximab
详细信息 查看全文
- 作者：Maria Gazouli ; Athanasios K. Anagnostopoulos ; Aggeliki Papadopoulou ; Anna Vaiopoulou ; Konstantinos Papamichael ; Gerassimos Mantzaris ; George E. Theodoropoulos ; Nicholas P. Anagnou ; George Th. Tsangaris
- 关键词：Inflammatory bowel disease ; Crohn's disease ; Infliximab ; Proteomics
- 刊名：Journal of Crohn's and Colitis
- 出版年：2013
- 出版时间：1 November, 2013
- 年：2013
- 卷：7
- 期：10
- 页码：e461-e470
- 全文大小：666 K
文摘
The infliximab (IFX) has dramatically improved the treatment of Crohn's disease (CD). However, the need for predictive factors, indicative of patients' response to IFX, has yet to be met. In the current study, proteomics technologies were employed in order to monitor for differences in protein expression in a cohort of patients following IFX administration, aiming at identifying a panel of candidate protein biomarkers of CD, symptomatic of response to treatment. We enrolled 18 patients, who either had achieved clinical and serological remission (Rm, n = 6), or response (Rs, n = 6) and/or were PNRs (n = 6), to IFX. Serum samples were subjected to two-dimensional Gel Electrophoresis. Following evaluation of densitometrical data, protein spots exhibiting differential expression among the groups, were further characterized by MALDI-TOF-MS. Identified proteins where evaluated by immunoblot analysis while functional network association was carried out to asses significance. Proteins apolipoprotein A-I (APOA1), apolipoprotein E (APOE), complement C4-B (CO4B), plasminogen (PLMN), serotransferrin (TRFE), beta-2-glycoprotein 1 (APOH), and clusterin (CLUS) were found to be up-regulated in the PNR and Rs groups whereas their levels displayed no changes in the Rm group when compared to baseline samples. Additionally, leucine-rich alpha-2-glycoprotein (A2GL), vitamin D-binding protein (VTDB), alpha-1B-glycoprotein (A1BG) and complement C1r subcomponent (C1R) were significantly increased in the serum of the Rm group. Through the incorporation of proteomics technologies, novel serum marker-molecules demonstrating high sensitivity and specificity are introduced, hence offering an innovative approach regarding the evaluation of CD patients' response to IFX therapy.